Allogene Therapeutics (ALLO) Profit After Tax (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Profit After Tax data on file, last reported at -$43.1 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 27.75% year-over-year to -$43.1 million; the trailing twelve-month figure through Mar 2026 stood at -$173.6 million (up 31.24% YoY), and the FY2025 full-year result was -$190.5 million, up 25.78% from the prior year.
• Profit After Tax eased to -$43.1 million in Q1 2026, from -$38.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$38.5 million in Q4 2025 to a low of -$100.0 million in Q1 2023.
• A 5-year average of -$67.6 million and a median of -$66.3 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax plunged 3438.56% in 2022 and soared 37.97% in 2025, its largest moves.
• Tracing ALLO's Profit After Tax over 5 years: stood at -$97.3 million in 2022, then increased by 21.04% to -$76.8 million in 2023, then increased by 21.64% to -$60.2 million in 2024, then surged by 36.11% to -$38.5 million in 2025, then dropped by 11.98% to -$43.1 million in 2026.
• Business Quant data shows ALLO's Profit After Tax at -$43.1 million in Q1 2026, -$38.5 million in Q4 2025, and -$41.1 million in Q3 2025.